Chris Karlovich1, Jonathan W. Goldman2, Jong-Mu Sun3, Elaina Mann1, Lecia V. Sequist4, Krzysztof Konopa5, Wei Wen6, Philipp Angenendt7, Leora Horn8, David Spigel9, Jean-Charles Soria10, Benjamin Solomon11, D. Ross Camidge12, Shirish Gadgeel13, Cloud Paweletz14, Lin Wu6, Sean Chien6, Patrick O'Donnell6, Shannon Matheny1, Darrin Despain1, Lindsey Rolfe1, Mitch Raponi1, Andrew R. Allen1, Keunchil Park3, and Heather Wakelee15
1Clovis Oncology Inc., San Francisco, California. 2University of California Los Angeles, Los Angeles, California. 3Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea. 4Massachusetts General Hospital, Boston, Massachusetts. 5Medical University of Gdansk, Gdansk, Poland. 6Roche Molecular Systems, Pleasanton, California. 7Sysmex Inostics GmbH, Hamburg, Germany. 8Vanderbilt University School of Medicine, Nashville, Tennessee. 9Sarah Cannon Research Institute, Nashville; Tennessee. 10Institut Gustave Roussy, Villejuif, France. 11University of Melbourne, Melbourne, Australia. 12University of Colorado, Denver, Colorado. 13Karmanos Cancer Institute/Wayne State University, Detroit, Michigan. 14Dana-Farber Cancer Institute, Boston, Massachusetts. 15Stanford University, Stanford, California
C. Karlovich, J. Goldman, J.-M. Sun, H. Wakelee, and K. Park contributed equally to this article.
Corresponding Authors: Jonathan W. Goldman, University of California Los Angeles, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA 90404. and Heather Wakelee